AstraZeneca paid $240M upfront + up to $180M technical milestones (total $420M) for 5-year exclusive option on mRNA targets in cardiometabolic plus selected oncology; up to 40 candidate selections plus dev/commercial milestones and royalties.
Did it work? Outcome assessment
Strategic verdict
Too Early
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedMar 21, 2013
ClosedMar 21, 2013
Deal value$420M
Deal typeLicensing/Option
Therapeutic areaCardiovascular, metabolic, renal disease and oncology
IndicationsCardiovascular, metabolic, renal disease and oncology